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Abstract
Purpose This study aims to compare the efficacy and safety
of oral palonosetron with intravenous (IV) palonosetron for
the prevention of cisplatin-related chemotherapy-induced nau-
sea and vomiting (CINV).
Methods A multinational, randomized, double-blind study
enrolling adult chemotherapy-naive patients with malignant
solid tumors scheduled to receive cisplatin-based highly
emetogenic chemotherapy (HEC). Patients received oral
palonosetron (0.50 mg) or IV palonosetron (0.25 mg), each
with oral dexamethasone. The primary objective was to dem-
onstrate non-inferiority in terms of patients with a complete
response (CR, no emesis/no rescue medication) within the
acute phase (0–24 h after chemotherapy administration).
Results Of the 743 patients randomized, 739 received study
medications and 738 were included in the full analysis set. The
CR rate in the acute phase was high for both groups (oral
89.4 %; IV 86.2 %). As this difference in proportions (stra-
tum-adjusted Cochran-Mantel-Haenszel method) was 3.21 %
(99 % confidence interval (CI) −2.74 to 9.17 %), non-
inferiority was demonstrated (since the lower limit of the
99 % CI was closer to zero than the predefined margin of
15 %). Treatment-emergent adverse events (TEAEs) related
to the study drug were rare (oral 3.2 %; IV 6.5 %). No TEAEs
related to study drug leading to discontinuation were reported.
Conclusion Non-inferiority of oral versus IV palonosetron was
demonstrated. The CR rate in the acute phase was >86 % in
both patient groups. The safety profiles were comparable.
Keywords Palonosetron . Highly emetogenic chemotherapy
(HEC) . Chemotherapy-induced nausea and vomiting
(CINV) . Cisplatin
Introduction
Cisplatin-based chemotherapy regimens are a cornerstone of
curative cancer treatment for non-seminomatous germ cell
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Efficacy and safety of oral palonosetron compared with IV
palonosetron administered with dexamethasone
for the prevention of chemotherapy-induced nausea and vomiting
(CINV) in patients with solid tumors receiving cisplatin-based
highly emetogenic chemotherapy (HEC)
tumors and a standard treatment for most advanced lung
and some gas t r o i n t e s t i n a l c ance r s ; howeve r ,
chemotherapy-induced nausea and vomiting (CINV) is
a major side effect [1, 2]. Currently, neurokinin 1
(NK1) and 5-hydroxytryptamine 3 (5-HT3) receptor an-
tagonists (RAs), used in combination with steroids such
as dexamethasone, are recommended to control CINV
related to cisplatin-based highly emetogenic chemother-
apy (HEC) [3].
Palonosetron (Aloxi®, Oncit®, Paloxi®) is a potent and
selective second-generation 5-HT3 RAwhich has demonstrat-
ed efficacy in the management of CINV when administered
both intravenously (IV) and orally [4]. Its prolonged duration
of action offers significant advantages over the other 5-HT3
RAs for the prevention of CINV in patients with cancer re-
ceiving both moderately and HEC regimens [5–9].
Palonosetron has also been shown to be effective in managing
CINV associated with a variety of chemotherapeutic agents
across a range of indications [10–19].
Clinical studies of CINV prevention with oral and IV
palonosetron doses ranging from 0.1 to 90 μg/kg have been
performed. The clinical development of IV palonosetron for
the prevention of CINV comprised three efficacy studies, two
in moderately emetogenic CINV [20, 21] and one in highly
emetogenic CINV [22], which evaluated the efficacy and safe-
ty of two palonosetron doses, 0.25 and 0.75 mg, against doses
of approved comparators (ondansetron and dolasetron). The
studies reported that 0.25 mg IV palonosetron was the most
effective for the prevention of both moderately and highly
emetogenic CINVover the study period (0–120 h).
The safety and efficacy of oral palonosetron was based on
the results of a double-blind, randomized study, which evalu-
ated the efficacy of single oral doses of 0.25, 0.50, and
0.75 mg palonosetron, versus 0.25 mg IV palonosetron,
with/without the concomitant administration of dexametha-
sone, for the prevention of moderately emetogenic CINV.
The study reported that 0.50 mg was the lowest effective oral
dose of palonosetron for the prevention of moderately
emetogenic CINV [4].
In this multicenter, randomized, double-blind study, we
investigated the efficacy and safety of 0.50 mg oral
palonosetron, compared with 0.25 mg IV palonosetron, for
the prevention of CINV induced by cisplatin-based HEC in
patients with malignant solid tumors.
The objective of this study was to demonstrate the efficacy
of 0.50 mg oral palonosetron for the prevention of highly
emetogenic CINV. Evidence of efficacy would confirm the
contribution of the 0.50 mg oral palonosetron component to
a netupitant/palonosetron fixed-dose combination product,
developed for the prevention of nausea and vomiting induced
by HEC, and the suitability of 0.50 mg oral palonosetron as an
active comparator in other CINV clinical studies conducted
with fixed-dose combination products.
Patients and methods
Study design
This was a phase III, multicenter (60 centers), multinational,
randomized, double-blind, double-dummy, parallel group-
stratified study to assess the efficacy and safety of 0.50 mg
oral palonosetron in comparison with 0.25 mg IV
palonosetron in patients with solid tumors receiving
cisplatin-based HEC (EudraCT number: 2010-022223-29).
The stratification criteria were gender (male and female) and
region (USA, Latin America, Europe, Asia, and the Common-
wealth of Independent States).
The trial protocol and documentation were reviewed and
approved by the relevant institutional review boards, ethics
committees, and health authorities. The trial was conducted
in accordance with the International Conference on Harmoni-
zation Guidelines for Good Clinical Practice and applicable
local regulations as well as the Declaration of Helsinki (1964,
amended in 1975, 1983, 1989, 1996, and 2000). All patients
provided written informed consent.
Inclusion criteria
Chemotherapy-naive male and female patients receiving a
cisplatin-based HEC regimen, aged ≥18 years with histologi-
cally or cytologically confirmed malignant solid tumors and
an Eastern Cooperative Oncology Group (ECOG) perfor-
mance status of 0–2, were enrolled in this study. Additional
inclusion criteria included adequate hepatic, renal, and hema-
tological function.
Exclusion criteria
Patients could not receive moderately or HEC from days 2–5
following cisplatin administration, radiation therapy to the
abdomen or the pelvis within 1 week prior to day 1 or between
days 1 and 5, and any medication with known or potential
antiemetic efficacy within 24 h prior to day 1. Additional
exclusion criteria included symptomatic primary or metastatic
CNS malignancy and grade ≥1 vomiting, retching, and mild
nausea (as defined by the National Cancer Institute) within
24 h prior to day 1.
Patient treatment
All patients were scheduled to receive their first course of
cisplatin-based cytotoxic chemotherapy administered as a sin-
gle IV dose of ≥70 mg/m2 over 1–4 h on day 1, alone or in
combination with other chemotherapeutic agents.
Patients were randomized to one of the following treatment
groups: oral palonosetron 0.50 mg or IV palonosetron
0.25 mg. Both groups received oral dexamethasone 20 mg
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on day 1, followed by dexamethasone (8 mg) twice daily (bid)
on days 2–4.
The use of rescue medication for the treatment of nausea/
vomiting was allowed after the start of the chemotherapy ad-
ministration; however, this was considered as a treatment fail-
ure. Metoclopramide tablets were provided, and the investiga-
tor was authorized to use an alternative rescue treatment at
their discretion. However, the use of 5-HT3 RAs was discour-
aged and the use of palonosetron was not permitted.
Endpoints
The primary study objective was to demonstrate the non-
inferiority of single-dose oral palonosetron 0.50 mg versus
single-dose IV palonosetron 0.25 mg. The primary efficacy
endpoint was the proportion of patients with a complete re-
sponse (CR, defined as no emesis and no rescue medication)
within 24 h (acute phase) of the start of HEC administration on
day 1.
Secondary study objectives were to assess the efficacy of
single-dose 0.50 mg oral palonosetron versus single-dose
0.25 mg IV palonosetron during the delayed and overall phases
and to evaluate the safety and tolerability of 0.50 mg oral
palonosetron versus IV palonosetron in preventing CINV. Sec-
ondary efficacy endpoints included the CR rate for the delayed
(25–120 h) and overall (0–120 h) phases, the severity of nausea,
the percentage of patients with complete protection (CP, de-
fined as no vomiting, no rescue therapy, and no nausea), the
percentage of patients without emesis, and the percentage of
patients without rescue medication for the delayed and overall
phases. Time to treatment failure (TTF), defined as the time to
the first emetic episode or the administration of rescue medica-
tion, was also investigated. The impact of palonosetron on QoL
using the modified Functional Living Index-Emesis (FLIE)
questionnaire was also investigated [23]. Time-related efficacy
assessments commenced at the time of cisplatin administration
(time zero). Efficacy parameters were evaluated in the acute,
delayed, and overall phases. Safety assessments included phys-
ical examination, vital signs, 12-lead electrocardiogram (ECG),
laboratory analysis (hematology, blood chemistry, urinalysis),
and adverse events (AEs).
AEs were coded using the Medical Dictionary for Regula-
tory Activities (MedDRA), version 14.0. The incidence of
treatment-emergent adverse events (TEAEs) in each treatment
groupwas assessed. Clinical laboratory data were summarized
using frequency tables for values within/outside reference
ranges, and shift tables were used to evaluate changes in clin-
ical laboratory data versus baseline.
Statistical analysis
The full analysis set (FAS) comprised all patients who were
randomized to treatment and received at least one
chemotherapy regimen and the study medication. The FAS
was used to analyze patient demographic and baseline charac-
teristics and primary and secondary efficacy endpoints. The
per-protocol (PP) population comprised all patients included
in the FAS who completed the 0–24-h study period with no
major protocol violations, i.e., those affecting the primary ef-
ficacy endpoint. The PP population was also used for demo-
graphic and other baseline characteristics and primary efficacy
analysis. The safety population was used for all safety analy-
ses and comprised all patients who received at least one dose
of study medication and had at least one safety assessment
after treatment administration.
For non-inferiority testing, calculations were based on the
two-sided stratum-adjusted Cochran-Mantel-Haenszel
(CMH) method for the proportion of patients with CR in the
acute phase. The model included gender and region as strata.
The non-inferiority of oral palonosetron would be established
if the lower limit of the two-sided 99 % confidence intervals
(CIs) for the difference between oral palonosetron and IV
palonosetron was greater (i.e., closer to zero) than the
prespecified non-inferiority margin, which was set at −15 %.
For a two-sided test of difference using a type I error of 0.010,
a sample size of 322 evaluable patients per treatment group
was required to ensure 90 % power (nQuery Advisor, version
6.0, module PTEO1). This was revised up to 370 per treatment
group in order to ensure an adequate number of evaluable
patients.
For the secondary efficacy endpoints, no test for non-
inferiority was performed. The comparison between treat-
ments was performed using a CMH test including gender
and region as factors. The results are presented using odds
ratios (ORs), two-sided 95 % CIs for the ORs, and p values.
Results
Baseline characteristics
Between 21 June 2011 and 14 November 2012, a total of 743
patients were enrolled and randomized as 1:1 to receive oral
and IV palonosetron. Of these, 739 (99.5 %) received study
medications and were included in the safety population and
738 were included in the FAS. Of the 743 randomized pa-
tients, 33 (4.4 %) discontinued the study after randomization.
The main reasons for discontinuation were death which was
reported in 6 (1.6 %) patients in the oral palonosetron group
and 11 (3.0 %) patients in the IV palonosetron group; with-
drawal of consent in 2 (0.5 %) and 3 (0.8 %) patients, respec-
tively; and loss to follow-up in 1 (0.3 %) and 3 (0.8 %) pa-
tients, respectively. Deaths observed during the study were
generally due to the patient’s underlying cancer and disease
progression. No deaths were considered to be due to
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palonosetron. In total, 710 (95.6 %) patients completed the
study.
The majority of patients in the safety population were male
(59.3 %) and white (86.7 %) with a mean age of 57.9 years.
Overall, nearly half (46.5 %) of all the patients had
lung/respiratory tract cancer. Patient baseline characteristics
were generally comparable in both treatment arms and are
summarized in Table 1.
Efficacy
The percentage of patients (FAS) with a CR in the acute phase
was 89.4 % in the oral palonosetron group and 86.2 % in the
IV palonosetron group (Fig. 1). The difference in the propor-
tions of responders (stratum-adjusted CMH method) in the
FAS was 3.21 % (99 % CI −2.74 to 9.17 %) (Table 2). The
non-inferiority of oral palonosetron versus IV palonosetron
was demonstrated since the lower limit of the two-sided
99 % CI for the difference in proportions was greater than
the predefined non-inferiority margin set at −15%. Consistent
results were obtained in the PP population with a difference in
proportions between the oral and IV palonosetron groups of
3.77 % (99 % CI −3.22 to 10.76 %). The CR rates were also
similar in both the delayed (76.2 vs 74.8 % for oral and IV
Table 1 Patient baseline and disease characteristics (safety population)
Oral palonosetron (n=370) IV palonosetron (n=369) Overall (n=739)
Gender, n (%)
Male 219 (59.2) 217 (58.8) 436 (59.0)
Female 151 (40.8) 152 (41.2) 303 (41.0)
Ethnic origin, n (%)
White 321 (86.8) 320 (86.7) 641 (86.7)
Black 0 0 0
Asian 49 (13.2) 47 (12.7) 96 (13.0)
Hispanic 0 1 (0.3) 1 (0.1)
Other 0 1 (0.3) 1 (0.1)
Agea (years)
Mean (SD) 58.0 (9.41) 57.7 (9.92) 57.9 (9.66)
Primary cancer location, n (%)
Gastric 25 (6.8) 24 (6.5) 49 (6.6)
Head and neck 62 (16.8) 71 (19.2) 133 (18.0)
Lung/respiratory tract 174 (47.0) 170 (46.1) 344 (46.5)
Ovarian 15 (4.1) 18 (4.9) 33 (4.5)
Bladder 8 (2.2) 3 (0.8) 11 (1.5)
Other 86 (23.2) 83 (22.5) 169 (22.9)
Time since diagnosis (days)
n 370 368 738
Mean (SD) 92.7 (265.54) 66.8 (179.00) 79.8 (226.78)
Tumor extent at study entry, n (%)
Primary disease 184 (49.7) 193 (52.3) 377 (51.0)
Metastatic disease 176 (47.6) 161 (43.6) 337 (45.6)
Local recurrence 10 (2.7) 15 (4.1) 25 (3.4)
IV intravenous, SD standard deviation
a At randomization
Fig. 1 Complete response rates during the acute, delayed, and overall
phases (full analysis set)
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palonosetron; OR 1.09, 95 % CI 0.77–1.5, p=0.637) and
overall (73.7 vs 70.2 % for oral and IV palonosetron; OR
1.20, 95 % CI 0.87–1.67, p=0.269) phases (Fig. 1).
On individual study days, day 1 (0–24 h), day 2 (25–48 h),
day 3 (49–72 h), day 4 (73–96 h), and day 5 (97–120 h), the
percentage of responders was similar for both the oral
palonosetron and IV palonosetron groups. The results were
also similar for the cumulative time intervals.
There was no significant difference in the percentage of
patients with no emesis in the delayed (78.9 % oral
palonosetron, 77.5 % IV palonosetron; OR 1.09, 95 % CI
0.77–1.56, p=0.625) and overall (75.6 % oral palonosetron,
73.2 % IV palonosetron; OR 1.15, 95 % CI 0.82–1.60, p=
0.430) phases.
The percentage of patients with no nausea in the acute
phase was 4.6 % higher in the oral palonosetron group (80.2
vs 75.6 % in the IV group; p=0.129), while in the delayed and
overall phases, patients with no nausea in the oral and
IV palonosetron groups were respectively 57.5 vs 53.4 %
(p=0.276) and 51.8 and 47.4 % (p=0.241). No statistical dif-
ferences were evidenced between palonosetron oral and IV
groups on nausea data in all the acute delayed and overall
study phases.
There was no significant difference between patients with
no rescue medication in the acute (94.6 % oral palonosetron,
93.2 % IV palonosetron; OR 1.28, 95 % CI 0.69–2.36, p=
0.433), delayed (85.6 % oral palonosetron, 82.9 % IV
palonosetron group; OR 1.27, 95 % CI 0.84–1.92, p=
0.258), and overall (84.3 % oral palonosetron, 80.8 % IV
palonosetron; OR 1.32, 95 % CI 0.89–1.96, p=0.174) phases.
Safety
No abnormal clinical test results were reported, and the anal-
ysis of ECG data indicated that any changes were at compa-
rable interims of frequency for both treatment groups.
TEAEs were reported for approximately half of all patients
in each treatment group (48.6 and 51.8 % for the oral
palonosetron and IV palonosetron, respectively) (Table 3).
However, TEAEs which were related to the study drug were
Table 2 Summary of complete response in the acute, delayed, and






Response, n (%) 330 (89.4) 318 (86.2)
CMH risk difference, oral vs IV
palonosetron (99 % CI)
3.21 (−2.74 to 9.17)
Delayed phase
Response, n (%) 281 (76.2) 276 (74.8)
CMH odds ratio, oral vs IV
palonosetron (95 % CI)
1.09 (0.77–1.52)
CMH p value 0.637
Overall phase
Response, n (%) 272 (73.7) 259 (70.2)
CMH odds ratio, oral vs IV
palonosetron (95 % CI)
1.20 (0.87–1.67)
CMH p value 0.269
CI confidence interval, CMH Cochran-Mantel-Haenszel, IV intravenous
Table 3 Treatment-emergent
adverse events (safety population)
IV intravenous, TEAE treatment-
emergent adverse event





At least one TEAE 180 (48.6) 191 (51.8) 371 (50.2)
TEAE related to study drug 12 (3.2) 24 (6.5) 36 (4.9)
TEAE related to dexamethasone 21 (5.7) 20 (5.4) 41 (5.5)
Any related TEAE 27 (7.3) 37 (10.0) 64 (8.7)
TEAE leading to discontinuation
of study drug
1 (0.3) 1 (0.3) 2 (0.3)
TEAE related to study drug
leading to discontinuation
0 0 0
TEAE related to additional
study drug leading to
discontinuation
0 1 (0.3) 1 (0.1)
TEAE leading to death 7 (1.9) 12 (3.3) 19 (2.6)
Table 4 Serious treatment-emergent adverse events (safety population)






Serious TEAE 36 (9.7) 36 (9.8) 72 (9.7)
Serious TEAE related
to study drug
2 (0.5) 0 2 (0.3)
Serious TEAE related
to dexamethasone
4 (1.1) 4 (1.1) 8 (1.1)
Any serious related
TEAE
5 (1.4) 4 (1.1) 9 (1.2)
IV intravenous, TEAE treatment-emergent adverse event
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rare (3.2 and 6.5 % for oral palonosetron and IV palonosetron,
respectively) and no study drug-related TEAEs leading to dis-
continuation were reported (Table 3). The most frequently
reported TEAEs assessed as being related to the study drugs
were gastrointestinal disorders (1.6 and 3 % in the oral
palonosetron group and IV palonosetron group, respectively),
nervous system disorders (0.5 and 1.6 %, respectively), con-
stipation (1.4 and 2.4 %, respectively), and headache (0.5 and
1.6 %, respectively). The most frequently reported serious
TEAEs were neutropenia (1.4 and 2.4 % in the oral
palonosetron group and IV palonosetron group, respectively),
anemia (0.3 and 1.6 % in the oral palonosetron group and IV
palonosetron group, respectively), thrombocytopenia (0.5 and
1.4 % in the oral palonosetron group and IV palonosetron
group, respectively), and febrile neutropenia (0.8 and 1.1 %
in the oral palonosetron group and IV palonosetron group,
respectively).
Study drug-related TEAEs qualified as serious occurred in
two (0.5 %) patients in the oral palonosetron group (Table 4):
abdominal pain and constipation (one patient) and diarrhea
and asthenia (one patient). For both patients, the events were
resolved. No patients in the IV palonosetron group had serious
TEAEs assessed as being related to the study drugs.
The death of 7 (1.9 %) patients in the oral palonosetron
group and 12 (3.3 %) in the IV palonosetron group was clas-
sified as TEAEs. None of these deaths were assessed as being
related to the study drugs or dexamethasone.
Discussion
The efficacy of palonosetron in controlling CINV in patients
with cancer receiving treatment with a variety of chemother-
apy regimens has been demonstrated previously [10–19].
In this study, we reported that in the acute phase, the ma-
jority of patients (89.4 % in the oral palonosetron group and
86.2 % in the IV palonosetron group) achieved a CR. The
non-inferiority of oral palonosetron compared with IV
palonosetron was thus demonstrated, as assessed by the pri-
mary efficacy endpoint (CR in the acute phase) in both the
FAS and PP populations. All the planned sensitivity analyses
supported the conclusion of non-inferiority of oral
palonosetron compared with IV palonosetron. The two treat-
ment groups also showed comparable CR in the delayed and
overall phases, and the results of the secondary efficacy end-
points in all three phases were similar. Thus, the results of the
secondary efficacy endpoints also support the demonstration
of non-inferiority.
The safety of IV palonosetron has been demonstrated in
several phase III clinical trials [20–22, 24–26]. The present
study further supports these findings as the safety profiles of
oral palonosetron and IV palonosetron were comparable and
raised no new concerns.
The use of orally administered antiemetics for prophylaxis
of nausea and emesis in patients receiving HEC treatment, in
particular, for the control of nausea and vomiting on the first
day of cisplatin treatment has been questioned [27]. This trial
clearly demonstrated the non-inferiority of oral palonosetron
versus IV palonosetron administration when both are used
with dexamethasone. The use of oral palonosetron may be
beneficial as it would allow a more convenient prophylaxis
which is proven to be effective in controlling CINV caused by
HEC. This may be of particular help for patients who receive
treatment in an outpatient setting.
The investigators are aware that the study did not include
an NK1 RA, as recommended by guidelines. However, the
following of such guidelines in the clinical setting remains
low and it is still important to evaluate the contribution of
individual agents to CINV control [28]. In conclusion, this
study demonstrated the non-inferiority of oral palonosetron
versus IV palonosetron, in combination with dexamethasone,
in the prevention and control of CINV in cancer patients re-
ceiving cisplatin-based HEC.
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